Across TCGA pan-cancer cohorts, RN7SL260P RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of RN7SL260P’s most consistent transcriptional readouts.
The strongest signal is observed in thyroid carcinoma (THCA), where RN7SL260P RNA is repressed in tumor relative to normal tissue. In most cancer types RN7SL260P is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.
THCA are the cancer types where RN7SL260P tumor–normal differential expression is most reproducible.